Cargando…

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies, and the incidence of RCC continues to rise worldwide. Although RCC can be treated with surgery at an early stages, the five-year survival rates have been observed to decline dramatically in patients with advanced disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Sifan, Dai, Jie, Ma, Meng, Xu, Tianxiao, Kong, Yan, Cui, Chuanliang, Chi, Zhihong, Si, Lu, Tang, Huan, Yang, Lu, Sheng, Xinan, Guo, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420644/ https://www.ncbi.nlm.nih.gov/pubmed/30874541 http://dx.doi.org/10.1038/s41419-019-1488-2

Ejemplares similares

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma
por: Yu, Sifan, et al.
Publicado: (2018)

miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy
por: Tang, Huan, et al.
Publicado: (2019)

High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis
por: Xu, Tianxiao, et al.
Publicado: (2018)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
por: Wu, Xiaowen, et al.
Publicado: (2017)

Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma
por: Yan, Junya, et al.
Publicado: (2018)

The E3 ubiquitin ligase RBCK1: Implications in the tumor immune microenvironment and antiangiogenic therapy of glioma
por: Guo, Jing, et al.
Publicado: (2023)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
por: Yu, Jiayi, et al.
Publicado: (2018)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
por: Ma, Meng, et al.
Publicado: (2019)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: Erratum
por: Ma, Meng, et al.
Publicado: (2022)

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon
por: Yu, Jiayi, et al.
Publicado: (2017)

RBCK1 promotes hepatocellular carcinoma metastasis and growth by stabilizing RNF31
por: Chen, Xijun, et al.
Publicado: (2022)

Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing
por: Yu, Jiayi, et al.
Publicado: (2019)

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma
por: Dai, Jie, et al.
Publicado: (2017)

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
por: Chi, Zhihong, et al.
Publicado: (2011)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma
por: Dai, Jie, et al.
Publicado: (2020)

A novel variant of RBCK1 gene causes mild polyglucosan myopathy
por: AlAnzi, Talal, et al.
Publicado: (2022)

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients
por: Wang, Xuan, et al.
Publicado: (2019)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis
por: Li, Zhongbo, et al.
Publicado: (2022)

Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
por: Cui, Chuanliang, et al.
Publicado: (2021)

RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling
por: Niu, Zhiguo, et al.
Publicado: (2022)

TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination
por: Chen, Jia-xin, et al.
Publicado: (2021)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
por: Zhou, Li, et al.
Publicado: (2021)

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study
por: Wei, Xiaoting, et al.
Publicado: (2019)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
por: Yu, Huan, et al.
Publicado: (2017)

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure()
por: Cui, ChuanLiang, et al.
Publicado: (2018)

Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53
por: Chen, Yajie, et al.
Publicado: (2019)

MICAL2 Mediates p53 Ubiquitin Degradation through Oxidating p53 Methionine 40 and 160 and Promotes Colorectal Cancer Malignance
por: Lu, Jinping, et al.
Publicado: (2018)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
por: Cui, ChuanLiang, et al.
Publicado: (2022)

Retraction of “MICAL2 Mediates p53 Ubiquitin Degradation through Oxidating p53 Methionine 40 and 160 and Promotes Colorectal Cancer Malignance”
por: Lu, Jinping, et al.
Publicado: (2021)

Pax3 Stimulates p53 Ubiquitination and Degradation Independent of Transcription
por: Wang, Xiao Dan, et al.
Publicado: (2011)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation
por: Wei, Meng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kcqs4fdr2ddck6v2c320r1ucrl